Cassava Sciences, Inc. ($SAVA) Stock Forecast: Down 5.4% Today

What is Cassava Sciences, Inc.?

Cassava Sciences (SAVA) is a pharmaceutical company listed on the NASDAQ. The company focuses on developing drugs for Alzheimer's disease.

Why is Cassava Sciences, Inc. going down?

SAVA stock is down 5.4% on Jan 26, 2026 20:05

• SAVA was downgraded to a "sell" rating, potentially sparking a bearish sentiment among investors.
• Despite surpassing earnings estimates, the overall consensus rating remains "Reduce" with a low average price target of $2.00, possibly contributing to the prevailing negative sentiment.
• The mixed signals from the earnings performance versus the "sell" rating could have resulted in uncertainty, fueling the significant bearish trend observed in SAVA's stock price.

SAVA Price Chart

SAVA Technical Analysis

SAVA News

Cassava Sciences (NASDAQ:SAVA) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen has downgraded Cassava Sciences (NASDAQ:SAVA) from a "hold" to a "sell" rating. This follows a previous "sell (e+)" rating from Weiss Ratings. The company has a consensus "Reduce" rating and an average price target of $2.00, despite recently beating earnings estimates.

https://www.marketbeat.com/instant-alerts/cassava-sciences-nasdaqsava-lowered-to-sell-rating-by-wall-street-zen-2026-01-24/

Trending Today

Bitcoin ($BTC) Crypto Forecast: Down 8.9% Today

Silver ($XAG) Commodity Forecast: Down 23.0% Today

Copper ($COPPER) Commodity Forecast: Down 5.2% Today

TRON ($TRX) Crypto Forecast: Down 5.1% Today

Ethereum ($ETH) Crypto Forecast: Down 14.1% Today

Gold ($XAU) Commodity Forecast: Down 5.1% Today

Estee Lauder Companies Inc. (The) ($EL) Stock Forecast: Down 18.7% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 13.6% Today

Cummins Inc. ($CMI) Stock Forecast: Down 11.0% Today

Qualys Inc. ($QLYS) Stock Forecast: Down 1.2% Today

Cassava Sciences, Inc. Price History

14.00.2026 - SAVA Stock was up 5.6%

• Despite disappointing Phase 3 trial results for simufilam in Alzheimer’s disease, Cassava Sciences experienced a strong bullish movement.
• The announcement of pivoting towards developing simufilam for TSC-related epilepsy might have sparked investor optimism and interest in the company's future prospects.
• The increased volume of call options being bought, along with insider buying and institutional investment, could indicate a belief in the potential success of the new development direction despite the challenges faced by the company.
• The stock price increase could also be influenced by short-term speculative trading rather than a reflection of the company's long-term outlook.

23.08.2025 - SAVA Stock was up 25.3%

• SAVA stock saw a notable uptrend following the CEO's acquisition of shares at a premium price, suggesting a confidence in the company's future trajectory.
• The recent Form 4 filing documenting the CEO's purchase likely bolstered investor trust and indicated internal confidence in the company's initiatives for Alzheimer's disease drug development.
• The disclosure of insider purchasing activity may have contributed to heightened investor confidence, resulting in a surge in stock value as market participants viewed it as a positive indicator of the company's advancements in the healthcare sector.

21.00.2026 - SAVA Stock was up 6.3%

• The upward movement in SAVA today may be linked to positive developments or speculation surrounding the advancement of its Alzheimer's drug, simufilam.
• Investors could be reacting to recent updates on the clinical trials or regulatory approval process, leading to a rise in the stock price.
• The risky nature of Cassava Sciences might also be attracting investors seeking potential high returns despite the volatility.

22.11.2025 - SAVA Stock was up 6.3%

• SAVA's stock rose despite encountering a setback with an FDA clinical hold on a proposed trial for Simufilam in TSC-related epilepsy.
• Investor optimism may stem from expectations that the company can meet FDA requirements for the trial, prompting the market's bullish response.
• Speculation on Cassava Sciences' future performance in neurology research could be driving the positive market sentiment.
• The bullish movement reflects investor confidence in the company's ability to navigate regulatory hurdles and advance its research endeavors in neurological disorders.

01.03.2025 - SAVA Stock was down 9.4%

• SAVA stock experienced a significant decline due to the failure of another late-stage study on its Alzheimer's disease candidate, raising concerns about its future growth prospects.
• The stock may have reached oversold territory, suggesting that the heavy selling pressure might have subsided, potentially paving the way for a turnaround.
• Analysts showing strong agreement in revising earnings estimates higher could indicate a positive shift in sentiment towards the stock, despite the recent setbacks.
• The uncertainty surrounding SAVA's growth prospects following the study failure has likely contributed to the bearish movement in the stock price today.

31.02.2025 - SAVA Stock was down 5.2%

• Cassava Sciences encountered a setback with the unsuccessful late-stage study of its Alzheimer's disease drug candidate.
• Concerns about the company's future growth prospects have arisen due to the trial's failure.
• Investors might be cautious about uncertainties related to Cassava Sciences' pipeline and market opportunities in Alzheimer's treatment.
• The adverse developments likely contributed to the notable bearish movement in SAVA stock today.

16.00.2026 - SAVA Stock was down 5.2%

• Cassava Sciences unveiled the outcomes of its Phase 3 clinical trials for simufilam targeting Alzheimer's disease, indicating that the drug fell short of its primary, secondary, and exploratory objectives. As a result, the Alzheimer's program was terminated.
• Despite this setback, Cassava Sciences is redirecting its efforts towards developing simufilam for epilepsy related to tuberous sclerosis complex (TSC), although it is encountering obstacles like a recent FDA clinical hold on its proposed trial for this new use.
• The company is grappling with financial difficulties, marked by substantial net losses and a settlement for a securities class action lawsuit. These challenges likely contributed to the recent market downturn as investors respond to the uncertainties surrounding Cassava Sciences' future in the pharmaceutical domain.

23.11.2025 - SAVA Stock was down 5.3%

• SAVA stock plummeted by 24% due to the FDA placing a full clinical hold on its proposed proof-of-concept trial for simufilam in TSC-related epilepsy, leading to investor concerns and a bearish sentiment.
• The announcement of a $31.25 million settlement to end a securities class action lawsuit from 2021, although not an admission of fault, might have added to the negative sentiment surrounding the stock.
• With setbacks in previous trials for simufilam in Alzheimer's disease and now in epilepsy, investors are wary of the company's ability to successfully develop and bring its treatments to market, contributing to the bearish movement in the stock price.
• The delays in trial initiation and the FDA's requirements for additional information and protocol modifications have raised uncertainties about the future timeline and success of simufilam, further impacting the stock's performance negatively.

30.11.2025 - SAVA Stock was down 6.3%

• The bearish movement observed in SAVA stock today might be linked to the resolution of a consolidated securities class action lawsuit for $31.25 million. While not admitting fault, this settlement could have raised concerns among investors regarding the company's corporate governance and legal matters.
• The recent FDA clinical hold on Cassava Sciences' proposed simufilam clinical trial for TSC-related epilepsy may have also contributed to the negative sentiment. Investors could be anxious about the delays in advancing this significant drug candidate.
• Shareholder engagement and discussions surrounding potential corporate governance adjustments, as brought up by Halper Sadeh LLC, may be heightening the uncertainty surrounding the stock. Investors might be exercising caution concerning the company's upcoming policies and decision-making procedures.
• Despite the obstacles, the resolution of the investor lawsuit and the company's concentration on advancing simufilam for TSC-related epilepsy could provide some hope for the future. Nevertheless, the stock could face fluctuations as investors analyze the consequences of these recent occurrences.

21.01.2025 - SAVA Stock was down 5.0%

• The bearish movement in SAVA's stock today could be attributed to investors' concerns about recent setbacks in the company's pipeline developmental plans.
• The anticipation of updates during the fourth-quarter earnings call might have raised uncertainties among investors, leading to a sell-off of the stock.
• The market might be reacting to any negative news or delays in Cassava's developmental milestones, causing a pessimistic sentiment among traders and resulting in the bearish movement of the stock today.

19.11.2025 - SAVA Stock was down 18.9%

• Concerns have arisen among investors due to the FDA's clinical hold on Cassava Sciences' simufilam trial, leading to a negative turn in the stock.
• The delay in commencing the trial beyond the first half of 2026 suggests potential setbacks in the development timeline, resulting in uncertainty for shareholders.
• Shareholders may be apprehensive about the company's capacity to fulfill the FDA's requirements and the possible impact of this regulatory obstacle on the drug candidate's future outlook.
• The downward movement in SAVA's stock price reflects market unease regarding the consequences of the FDA's ruling on the company's overall drug development plan and timeline.

26.00.2026 - SAVA Stock was down 5.4%

• SAVA was downgraded to a "sell" rating, potentially sparking a bearish sentiment among investors.
• Despite surpassing earnings estimates, the overall consensus rating remains "Reduce" with a low average price target of $2.00, possibly contributing to the prevailing negative sentiment.
• The mixed signals from the earnings performance versus the "sell" rating could have resulted in uncertainty, fueling the significant bearish trend observed in SAVA's stock price.